Indication Criteria for Genetic Testing

Evaluation of validity and clinical utility

Indication criteria for disease:
Non-obstructive azoospermia, severe oligozoospermia [AZFa, AZFb, AZFc]

1. General information on authorship

Name and address of institution:
Name: Institute of Human Genetics, University Hospital Münster
Address: Vesaliusweg 12-14
Postcode: D-48149
City: Münster
Tel.: +49-251-83-55401
Fax: +49-251-83-55431
E-mail: wieacker@uni-muenster.de
Internet: http://humangenetik.klinikum.uni-muenster.de

Head of the institution:
Name: Prof. Dr. med. Peter Wieacker
Tel.: +49-251-83-55401
Fax: +49-251-83-55431
E-mail: wieacker@uni-muenster.de

Author of this text, date:
Name: Prof. Dr. med. Peter Wieacker
Tel.: +49-251-83-55401
Fax: +49-251-83-55431
E-mail: wieacker@uni-muenster.de
Date: 07.10.2007

Reviewer, validation date:
Name: Prof. Dr. med. Wolfgang Engel
Tel.: +49-551-39-7589
Fax: +49-551-39-9303
E-mail: wengel@gwdg.de
Date: 22.11.2007

Translator, translation date:
Name: Prof. Dr. Ulrich Langenbeck
E-mail: Ulrich.Langenbeck@gmx.net
Date: 10.03.2008

Re-editor, date:
Name: 
Tel.: 
Fax: 
E-mail: 
Date: 

german society of human genetics
www.gfhev.de

Ad hoc Committee „Indication Criteria for Genetic Testing”
Ad hoc-Kommission „Indikationskriterien für genetische Diagnostik”

Chairman of the Committee
Prof. Dr. med. Jörg Schmidtke,
Institute of Human Genetics
Hannover Medical School
Carl-Neuberg-Str. 1
30625 Hannover
Tel. 0049 (0)511-532 6538
Fax 0049 (0)511 532 5865
schmidtke.joerg@mh-hannover.de

Members of the Committee
Prof. Dr. med. Gabriele Gillessen-Kaesbach
Prof. Dr. med. Tiemo Grimm
Prof. Dr. med. André Reis
Prof. Dr. med. Eberhard Schwinger
Prof. Dr. med. Peter Wieacker
Prof. Dr. med. Klaus Zerres
Prof. Dr. med. Johannes Zschocke

gfh Council (§26 BGB)
Prof. Dr. med. André Reis, Erlangen
Prof. Dr. med. Olaf Riess, Tübingen
Prof. Dr. med. Evelin Schröck, Dresden

gfh Office
Dipl.-Soz. Christine Scholz
Inselkammerstr. 5
82008 München-Unterhaching
Tel. 0049 (0)89-61 45 69 59
Fax 0049 (0)89-55 02 78 56
organisation@gfhev.de

Banking account
Postbank München
Konto 231 394 805
BLZ 700 100 80
IBAN DE19 7001 0080 0231 3948 05
BIC PBNK DEFF

register of associations Munich
VR 12341
2. Disease characteristics

2.1 Name of the Disease (Synonyms):
Non-obstructive Azoospermia / severe oligozoospermia

2.2 OMIM# of the Disease: 415000

2.3 Name of the Analysed Genes or DNA/Chromosome Segments:
AZFa, AZFb, and AZFc regions

2.4 OMIM# of the Gene(s): 415000

2.5 Mutational Spectrum:
deletions

2.6 Analytical Methods:
PCR

2.7 Analytical Validation
depends on region analysed

2.8 Estimated Frequency of the Disease in Germany
(Incidence at birth ("birth prevalence") or population prevalence):
Disordered spermatogenesis is found in 1% of all males. The prevalence of
AZF deletions is 15-20% in males with non-obstructive azoospermia and
7-10% in males with severe oligozoospermia. In unselected infertile males the
prevalence of AZF deletions is 0.6-1%.

2.9 If applicable, prevalence in the ethnic group of investigated person:
-

2.10 Diagnostic Setting:

A. (Differential)diagnostics

Yes. ☒
No. ☐

B. Predictive Testing

☐

C. Risk assessment in Relatives

☐

☐

D. Prenatal

☐

Comment:
Before ICSI, an AZF analysis may be important for therapeutic reasons
because, as a rule, no sperms are found on TESE in cases with AZFa and
AZFb deletions.
In contrast, 50% of males with AZFc deletions and an azoospermia in
ejaculate have sperms in testis.
3. Test characteristics

<table>
<thead>
<tr>
<th>genotype or disease</th>
<th>present</th>
<th>absent</th>
</tr>
</thead>
<tbody>
<tr>
<td>test</td>
<td>pos.</td>
<td>B</td>
</tr>
<tr>
<td></td>
<td>neg.</td>
<td>D</td>
</tr>
<tr>
<td>A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A: true positives  
B: false positives  
C: false negatives  
D: true negatives

3.1 Analytical Sensitivity  
(proportion of positive tests if the genotype is present)  
*nearly 100%*

3.2 Analytical Specificity  
(proportion of negative tests if the genotype is not present)  
*nearly 100%*

3.3 Clinical Sensitivity  
(proportion of positive tests if the disease is present)  
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.  
*The probability to find an AZF deletion in cases with non-obstructive azoospermia and normal karyotype is 15-20%. In cases with severe oligozoospermia this probability is 7-10%.*

3.4 Clinical Specificity  
(proportion of negative tests if the disease is not present)  
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.  
*Nearly 100%, because reduced penetrance is only rarely observed.*

3.5 Positive clinical predictive value  
(life time risk to develop the disease if the test is positive).  
*Nearly 100%, because reduced penetrance is only rarely observed.*

3.6 Negative clinical predictive value  
(Probability not to develop the disease if the test is negative).  
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.  
Index case in that family had been tested:  
*not applicable*  
Index case in that family had not been tested:  
*not applicable*
4. Clinical Utility

4.1 (Differential)diagnosis: The tested person ist clinically affected
(To be answered if in 2.10 "A" was marked)

4.1.1 Can a diagnosis be made other than through a genetic test?
No. ☐ (continue with 4.1.4)
Yes. ☒
clinically.
imaging.
endoscopy.
biochemistry.
electrophysiology.
other (please describe)

4.1.2 Describe the burden of alternative diagnostic methods to the patient
not applicable

4.1.3 How ist the cost effectiveness of alternative diagnostic methods to be judged?
not applicable

4.1.4 Will disease management be influenced by the result of a genetic test?
No. ☐
Yes. ☒
Therapy (please describe) In about half of the males with AZFc deletions sperms can be found on TESE. Therefore, a prior AZF analysis is useful.
Prognosis (please describe) see above
Management (please describe) see above
4.2 Predictive Setting: The tested person is clinically unaffected but carries an increased risk based on family history  
(To be answered if in 2.10 "B" was marked)

4.2.1 Will the result of a genetic test influence lifestyle and prevention?  
No.

If the test result is positive (please describe)  
not applicable

If the test result is negative (please describe)  
not applicable

4.2.2 Which options in view of lifestyle and prevention does a person at-risk have if no genetic test has been done (please describe)?  
not applicable

4.3 Genetic risk assessment in family members of a diseased person  
(To be answered if in 2.10 "C" was marked)

4.3.1 Does the result of a genetic test resolve the genetic situation in that family?  
Yes.

4.3.2 Can a genetic test in the index patient save genetic or other tests in family members?  
Yes.

4.3.3 Does a positive genetic test result in the index patient enable a predictive test in a family member?  
In most cases not.

4.4 Prenatal diagnosis  
(To be answered if in 2.10 "D" was marked)

4.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnostic?  
not useful

5. If applicable, further consequences of testing
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe)  
In case of a pregnancy after ICSI/TESE therapy, a son will inherit the father’s AZF deletion and will be infertile with high probability.